488 related articles for article (PubMed ID: 24131136)
1. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.
Joyce AT; Gandra SR; Fox KM; Smith TW; Pill MW
J Med Econ; 2014 Jan; 17(1):1-10. PubMed ID: 24131136
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
Bonafede MM; Gandra SR; Fox KM; Wilson KL
J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
[TBL] [Abstract][Full Text] [Related]
3. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
4. Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study.
Schabert VF; Bruce B; Ferrufino CF; Globe DR; Harrison DJ; Lingala B; Fries JF
Curr Med Res Opin; 2012 Apr; 28(4):569-80. PubMed ID: 22236091
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
Carter CT; Changolkar AK; Scott McKenzie R
J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
[TBL] [Abstract][Full Text] [Related]
6. Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice.
Huang X; Gu NY; Fox KM; Harrison DJ; Globe D
Curr Med Res Opin; 2010 Jul; 26(7):1637-45. PubMed ID: 20429830
[TBL] [Abstract][Full Text] [Related]
7. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
[TBL] [Abstract][Full Text] [Related]
8. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice.
Moots RJ; Haraoui B; Matucci-Cerinic M; van Riel PL; Kekow J; Schaeverbeke T; Davis A; Tedeschi MA; Freundlich B; Chang DJ; Singh A
Clin Exp Rheumatol; 2011; 29(1):26-34. PubMed ID: 21345289
[TBL] [Abstract][Full Text] [Related]
9. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
[TBL] [Abstract][Full Text] [Related]
10. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
[TBL] [Abstract][Full Text] [Related]
11. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.
Chastek B; Fox KM; Watson C; Gandra SR
Adv Ther; 2012 Aug; 29(8):691-7. PubMed ID: 22903239
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor-blocker dose escalation in rheumatoid arthritis patients in a pharmacy benefit management setting.
Blume SW; Fox KM; Joseph G; Chuang CC; Thomas J; Gandra SR
Adv Ther; 2013 May; 30(5):517-27. PubMed ID: 23740359
[TBL] [Abstract][Full Text] [Related]
13. Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice.
Ramírez-Herráiz E; Escudero-Vilaplana V; Alañón-Plaza E; Trovato-López N; Herranz-Alonso A; Morell-Baladrón A; Sanjurjo-Sáez M
Clin Exp Rheumatol; 2013; 31(4):559-65. PubMed ID: 23710583
[TBL] [Abstract][Full Text] [Related]
14. Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population.
Fisher MD; Watson C; Fox KM; Chen YW; Gandra SR
Curr Med Res Opin; 2013 May; 29(5):561-8. PubMed ID: 23489410
[TBL] [Abstract][Full Text] [Related]
15. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States.
Schabert VF; Watson C; Gandra SR; Goodman S; Fox KM; Harrison DJ
J Med Econ; 2012; 15(2):264-75. PubMed ID: 22115327
[TBL] [Abstract][Full Text] [Related]
16. Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice.
Blom M; Kievit W; Kuper HH; Jansen TL; Visser H; den Broeder AA; Brus HL; van de Laar MA; van Riel PL
Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1335-41. PubMed ID: 20506128
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
[TBL] [Abstract][Full Text] [Related]
18. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis.
Wu E; Chen L; Birnbaum H; Yang E; Cifaldi M
Curr Med Res Opin; 2008 Aug; 24(8):2229-40. PubMed ID: 18577308
[TBL] [Abstract][Full Text] [Related]
19. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
20. Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis.
Harrison DJ; Huang X; Globe D
Am J Health Syst Pharm; 2010 Aug; 67(15):1281-7. PubMed ID: 20651319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]